{"Clinical Trial ID": "NCT00236899", "Intervention": ["INTERVENTION 1:", "Treatment schedule (week)", "Weapons C, Docetaxel and Gemcitabine (Week):", "Docetaxel: 30 mg/m2, 30-60 min IV infusion on days 1, 8 and 15 to be administered 30 minutes before Gemcitabine, repeated every 28 days (weekly) for 10 cycles for RCs or RAs; 6 cycles for SD; or until PD.", "Gemcitabine: 800 mg/m2, 30 min IV infusion on days 1, 8 and 15 repeated every 28 days for 10 cycles for RCs or RAs; 6 cycles for SD; or up to PD.", "Army D, Paclitaxel and Gemcitabine (Week):", "Paclitaxel: 80 mg/m2, IV infusion approximately 1 hour, days 1, 8 and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for RCs or RAs; 6 cycles for SD; or up to PD.", "Gemcitabine: 800 mg/m2, 30 min IV infusion on days 1, 8 and 15 repeated every 28 days for 10 cycles for RCs or RAs; 6 cycles for SD; or up to PD.", "INTERVENTION 2:", "Treatment schedule (3 weeks)", "- Arm A, docetaxel and gemcitabine (3 weekly):", "Docetaxel: 75 mg/m2, 60 min IV infusion only on day 1, to be administered 30 min before Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for RCs or RAs; 6 cycles for SD; or until PD.", "Gemcitabine: 1000 mg/m2, 30 min IV infusion on days 1 and 8, repeated every 21 days for 10 cycles for RCs or RAs; 6 cycles for SD; or until PD.", "- Arm B, paclitaxel and gemcitabine (3 weekly):", "Paclitaxel: 175 mg/m2, IV infusion approximately 3 hours followed by Gemcitabine, repeated every 21 days (trimensual) for 10 cycles for RCs or RAs; 6 cycles for SD; or until PD.", "\u00b7 Gemcitabine: 1,250 mg/m2, 30 min IV infusion on days 1 and 8, repeated every 21 days for 10 cycles for RCs or RAs; 6 cycles for SD; or until PD."], "Eligibility": ["Incorporation criteria:", "- Histological diagnosis of metastatic breast cancer (MMC).", "A previous neoadjuvant or adjuvant taxa regime is allowed if 12 months after the end of the plan.", "Relapsing after receiving adjuvant/neoadjuvant chemotherapy containing anthracycline if it is not clinically contraindicated.", "Patients with measurable illness.", "A previous hormonal treatment for adjuvant adjustment or metastatic disease.", "- Exclusion criteria:", "Previous chemotherapy for BCM", "\u2022 Previous chemotherapy with gemcitabine in any context of disease", "The patient is eligible for treatment with trastuzumab."], "Results": ["Performance measures:", "Time spent on disease progression (TCPD) according to the treatment schedule", "The TTPD was censored at the time of the last follow-up for patients who were still alive without progression. The tumour response was evaluated in cancer patients using the Criteria for Assessing Response in Solid Tumours (RECIST), which define when cancer patients improve (\"respond\"), remain the same (\"stabilize\") or worsen (\"progress\") during treatment. The progressive disease is a 20% increase in the sum of the longer diameter of the target lesions.", "Time limit: Baseline up to 49.84 months", "Results 1:", "Title of arm/group: Treatment schedule (Week)", "Description of the arm/group: arms C, docetaxel and gemcitabine (week):", "Docetaxel: 30 mg/m, 30-60 min IV infusion on days 1, 8 and 15 to be administered 30 minutes before Gemcitabine, repeated every 28 days (weekly) for 10 cycles for RCs or RAs; 6 cycles for SD; or until PD.", "Gemcitabine: 800 mg/m, 30 min IV infusion on days 1, 8 and 15 repeated every 28 days for 10 cycles for RCs or RAs; 6 cycles for SD; or until PD.", "Army D, Paclitaxel and Gemcitabine (Week):", "Paclitaxel: 80 mg/m, IV infusion approximately 1 hour, days 1, 8 and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for RCs or RAs; 6 cycles for SD; or up to PD.", "Gemcitabine: 800 mg/m, 30 min IV infusion on days 1, 8 and 15 repeated every 28 days for 10 cycles for RCs or RAs; 6 cycles for SD; or until PD.", "Total number of participants analysed: 117", "Median (95% confidence interval)", "Unit of measure: months 8.33 (6.19 to 10.16)", "Results 2:", "Title of arm/group: Treatment schedule (3 weeks)", "- Arm/group description: arms A, docetaxel and gemcitabine (3 weekly):", "Docetaxel: 75 mg/m, 60 min IV infusion at first day only, to be administered 30 min before Gemcitabine, repeated every 21 days (trimensual) for 10 cycles for RCs or RAs; 6 cycles for SD; or until PD.", "Gemcitabine: 1000 mg/m, 30 min IV infusion on days 1 and 8, repeated every 21 days for 10 cycles for RCs or RAs; 6 cycles for SD; or until PD.", "- Arm B, paclitaxel and gemcitabine (3 weekly):", "Paclitaxel: 175 mg/m, IV infusion approximately 3 hours followed by Gemcitabine, repeated every 21 days (trimensual) for 10 cycles for RCs or RAs; 6 cycles for SD; or up to PD.", "\u00b7 Gemcitabine: 1250 mg/m, 30 min IV infusion on days 1 and 8, repeated every 21 days for 10 cycles for RCs or RAs; 6 cycles for SD; or until PD.", "Total number of participants analysed: 124", "Median (95% confidence interval)", "Unit of measure: month 7,51 (5,93 to 8,33)"], "Adverse Events": ["Undesirable Events 1:", "Total: 9/59 (15.25 per cent)", "Anemia 0/59 (0.00 %)", "Febrile neutropenia 1/59 (1.69%)", "Neutropenia 4/59 (6.78%)", "Thrombocytopenia 0/59 (0.00 %)", "Heart failure 0/59 (0.00 %)", "Pericardial infusion 0/59 (0.00 %)", "Diarrhoea 2/59 (3.39%)", "Intestinal occlusion 0/59 (0.00 %)", "Nausea 1/59 (1.69%)", "- Vomiting 1/59 (1.69%)", "Asthenia 0/59 (0.00 %)", "Fatigue 1/59 (1.69%)", "Adverse Events 2:", "Total: 10/62 (16.13 per cent)", "Anemia 1/62 (1.61%)", "- Febrile neutropenia 0.62 (0.00 per cent)", "Neutropenia 1/62 (1.61%)", "Thrombocytopenia 1/62 (1.61%)", "Heart failure 1/62 (1.61%)", "1/62 (1.61%)", "Diarrhoea 0.62 (0.00 %)", "Intestinal occlusion 0/62 (0.00 %)", "- Nausea 0.62 (0.00 per cent)", "- Vomiting 0.62 (0.00 %)", "Asthenia 0.62 (0.00 %)", "Fatigue 0.62 (0.00 %)"]}